... y las Tres últimas para este Miercoles 22 ... y a esperar que desde la Empresa nos lo expliquen bastante mejor ... :
11. Antitumor activity of Irvalec (PM02734) against lung cancer xenografts .
Ensayo con el Pariente del Kahalalide - F ... el Irvalec con demostrada actividad en Mama , Colon , Pancreas , Pulmón y Prostata . Este ensayo justifica el proseguir ensayos combinatorios con Erlotinib en Pacientes con Cancer de Pulmón .
******************************************************
12. Combination of plitidepsin and rituximab is effective for treatment of rituximab resistant Non-Hodgkin's B-cell lymphoma .
Ensayo del Aplidin que junto con Rituximab en Pacientes Linfoma No Hodgkin-B podria ser Viable .
******************************************************
13. ZNF93 overexpression is associated with ET-743 (Trabectedin; Yondelis®) and PM00104 (Zalypsis®) resistance in human cancer cell lines .
Differential expressions of ZNF93 and ZNF43 genes were confirmed in both CS-1/ER and CS-1/PR resistant cell lines. Furthermore, ZNF93 was overexpressed in two ET-743 resistant Ewing sarcoma cell lines as well as in a cisplatin resistant ovarian cancer cell line, but was not overexpressed in paclitaxel resistant cell lines. ZNF93 knockdown by siRNA in CS-1/ER and CS-1/PR caused increased sensitivity for ET-743, PM00104, and cisplatin. In conclusion, this study demonstrates that zinc finger proteins, specifically ZNF93, are involved in the resistance of ET-743 and PM00104.